Oral Genome
PrivateLast Round
SAFE
Jun 26, 2026
Est. Valuation
$375,000
Total Funding Raised
$110,000
Company Overview
Oral Genome operates in Healthcare & Life Sciences and is based in Carlsbad, California. Its latest recorded funding round was a SAFE round in June 2026.
Oral Genome is a biotechnology company that provides point-of-care salivary testing kits to analyze biomarkers for oral and systemic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Medical AI, Healthcare Analytics
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Oral Genome Comparables
Compare Oral Genome with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Drūl | 84% | |
| Spectrum Solutions | 79% | |
| SuperTruth | 77% |
For institutional investors. Book with your work email.
Oral Genome Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| SAFE | Jun 26, 2026 | ||||
| Strategic | Mar 5, 2024 | ||||
| Seed | Dec 1, 2022 | ||||
| Accelerator | Sep 10, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Oral Genome Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| American Dental Association | Strategic |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 17, 2025
Received the 2025 Cellerant Best of Class Hygiene Award for oral care innovation.
- Nov 7, 2025
Michael Shuman appointed as the new Chief Revenue Officer.
For institutional investors. Book with your work email.
Oral Genome Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Oral Genome's valuation, stock price, and market status.
Is Oral Genome a public or private company?
Oral Genome is a private company.
What is the current stock price of Oral Genome?
Oral Genome is a private company, so its shares have no public market price. Caplight tracks Oral Genome's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Oral Genome worth (valuation)?
Oral Genome's valuation is estimated at $375.0K based on funding round data.
Can I buy Oral Genome stock?
Oral Genome shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Oral Genome's last funding round?
Oral Genome's most recent funding round was SAFE on June 26, 2026.
Who are the main investors in Oral Genome?
Key investors in Oral Genome include American Dental Association.
Will Oral Genome IPO soon?
No public IPO plans have been announced for Oral Genome.
How can I track Oral Genome secondary market activity?
Caplight tracks bids, offers, and trades in Oral Genome's shares on secondary markets.